Barbara A Goff

Summary

Publications

  1. pmc Advanced ovarian cancer: what should be the standard of care?
    Barbara A Goff
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    J Gynecol Oncol 24:83-91. 2013
  2. doi request reprint Ovarian cancer: screening and early detection
    Barbara A Goff
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
    Obstet Gynecol Clin North Am 39:183-94. 2012
  3. doi request reprint Symptoms associated with ovarian cancer
    Barbara Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    Clin Obstet Gynecol 55:36-42. 2012
  4. pmc Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability
    Barbara A Goff
    University of Washington, Department of Obstetrics and Gynecology, Seattle, WA 98195 6460, USA
    Gynecol Oncol 124:230-5. 2012
  5. doi request reprint Training and assessment in gynaecologic surgery: the role of simulation
    Barbara A Goff
    Department of Obstetrics and Gynaecology, University of Washington School of Medicine, Seattle, 98195 6460, United States
    Best Pract Res Clin Obstet Gynaecol 24:759-66. 2010
  6. doi request reprint Involvement of gynecologic oncologists in the treatment of patients with a suspicious ovarian mass
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
    Obstet Gynecol 118:854-62. 2011
  7. doi request reprint How are symptoms of ovarian cancer managed? A study of primary care physicians
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    Cancer 117:4414-23. 2011
  8. doi request reprint Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
    Gynecol Oncol 116:340-4. 2010
  9. pmc Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 116:378-83. 2010
  10. pmc Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 123:461-6. 2011

Collaborators

Detail Information

Publications60

  1. pmc Advanced ovarian cancer: what should be the standard of care?
    Barbara A Goff
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    J Gynecol Oncol 24:83-91. 2013
    ..In addition, clinical trials are evaluating intraperitoneal, dose dense, antiangiogenic drugs as well as targeted maintenance therapies which will establish new standards of care in the near future...
  2. doi request reprint Ovarian cancer: screening and early detection
    Barbara A Goff
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
    Obstet Gynecol Clin North Am 39:183-94. 2012
    ..Finally, clinicians must always listen carefully to their patients avoid potentially harmful delays in diagnosis. Until there is a screening test, awareness is best...
  3. doi request reprint Symptoms associated with ovarian cancer
    Barbara Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    Clin Obstet Gynecol 55:36-42. 2012
    ..It is important for women and practitioners to be aware that ovarian cancer is not a "silent disease."..
  4. pmc Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability
    Barbara A Goff
    University of Washington, Department of Obstetrics and Gynecology, Seattle, WA 98195 6460, USA
    Gynecol Oncol 124:230-5. 2012
    ..Our goal was to determine if symptom-based ovarian cancer screening was feasible in a primary care clinic and acceptable to women and practitioners. In addition, we wanted to describe the outcomes for a pilot group of screened women...
  5. doi request reprint Training and assessment in gynaecologic surgery: the role of simulation
    Barbara A Goff
    Department of Obstetrics and Gynaecology, University of Washington School of Medicine, Seattle, 98195 6460, United States
    Best Pract Res Clin Obstet Gynaecol 24:759-66. 2010
    ..Most importantly, it requires desire on the part of the trainees to devote the hours of practise needed to make themselves accomplished surgeons...
  6. doi request reprint Involvement of gynecologic oncologists in the treatment of patients with a suspicious ovarian mass
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
    Obstet Gynecol 118:854-62. 2011
    ..To identify the factors associated with inclusion of a gynecologic oncologist in managing the care of a woman with suspected ovarian cancer...
  7. doi request reprint How are symptoms of ovarian cancer managed? A study of primary care physicians
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    Cancer 117:4414-23. 2011
    ..A study was undertaken to identify the diagnostic approaches that primary care physicians and gynecologists undertake in women with symptoms associated with ovarian cancer...
  8. doi request reprint Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
    Gynecol Oncol 116:340-4. 2010
    ..We hypothesized that women treated with alternative IP chemotherapy strategies may have less toxicity and improved compliance...
  9. pmc Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 116:378-83. 2010
    ..Prior studies suggest that combining the Symptom Index (SI) with a serum HE4 test or a CA125 test may improve prediction of ovarian cancer. However, these three tests have not been evaluated in combination...
  10. pmc Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 123:461-6. 2011
    ..While NAC may facilitate and simplify complete cytoreduction and reduce the risk of surgery, the delay of surgery related to NAC needs to be balanced against any potential benefit...
  11. ncbi request reprint Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas
    Vijaya Galic
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
    Genes Chromosomes Cancer 46:239-47. 2007
    ..04). Somatic mutation or deletion was equally common for either codon 72 allele. Age of diagnosis was not influenced by codon 72 but showed a trend for younger age in women with somatic TP53 mutations and the MDM2 G/G genotype...
  12. doi request reprint Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study
    Kathryn F McGonigle
    Women s Cancer Care of Seattle, Seattle, Washington 98133, USA
    Cancer 117:3731-40. 2011
    ..A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC)...
  13. pmc Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Neoplasia 12:993-1002. 2010
    ..The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry...
  14. pmc The temporal stability of the Symptom Index among women at high-risk for ovarian cancer
    Kimberly A Lowe
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 114:225-30. 2009
    ..To evaluate the temporal stability of self-reported symptoms known to be associated with ovarian cancer...
  15. pmc The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations
    Barbara M Norquist
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Cancer 116:5261-71. 2010
    ..BRCA1 or BRCA2 (BRCA1/2)-mutated ovarian carcinomas may originate in the fallopian tube. The authors of this report investigated alterations in BRCA1/2 tubal epithelium to define the molecular pathogenesis of these carcinomas...
  16. ncbi request reprint Predictors of comprehensive surgical treatment in patients with ovarian cancer
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington 98195 6460, USA
    Cancer 109:2031-42. 2007
    ..In this study, the authors identified factors that were associated with a measure of comprehensive surgery, so that interventions may be targeted appropriately to improve surgical care...
  17. ncbi request reprint Development of an ovarian cancer symptom index: possibilities for earlier detection
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98196 6460, USA
    Cancer 109:221-7. 2007
    ..Currently, screening for ovarian cancer is not recommended for the general population. Targeting women with specific symptoms for screening has been evaluated only recently, because it was believed that symptoms had limited specificity...
  18. doi request reprint Microparticles from ovarian carcinomas are shed into ascites and promote cell migration
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Int J Gynecol Cancer 22:546-52. 2012
    ....
  19. pmc Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas
    Elizabeth M Swisher
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Mol Cancer 8:48. 2009
    ..Additionally, we assessed whether promoter methylation of BRCA1, MLH1 or FANCF influenced response to chemotherapy or explained alterations in protein expression after chemotherapy exposure...
  20. doi request reprint Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?
    Laura Mae Baldwin
    University of Washington, Seattle, Washington 98195 4982, USA
    Ann Intern Med 156:182-94. 2012
    ..No professional society or group recommends routine ovarian cancer screening, yet physicians' enthusiasm for several cancer screening tests before benefit has been proven suggests that some women may be exposed to potential harms...
  21. pmc Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma
    Ruchi Garg
    Division of Gynecologic Oncology, University of Washington Medical Center, Seattle 98195, USA
    Gynecol Oncol 103:793-6. 2006
    ..The IL6 -174 promoter polymorphism impacts serum cytokine levels through transcriptional regulation. The objective of our study was to determine if -174 IL6 genotype influences survival in ovarian cancer...
  22. pmc Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly
    Melissa M Thrall
    Department of Obstetrics, University of Washington School of Medicine, University of Washington, Seattle, Washington 98195 6460, USA
    Obstet Gynecol 118:537-47. 2011
    ..To identify factors associated with increased 30-day mortality after advanced ovarian cancer debulking among elderly women...
  23. ncbi request reprint Comparison of objective, structured assessment of technical skills with a virtual reality hysteroscopy trainer and standard latex hysteroscopy model
    Barbara A Goff
    Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
    J Reprod Med 52:407-12. 2007
    ..To evaluate a virtual reality (VR) hysteroscopy device and a standard latex hysteroscopy model for assessment of residents' surgical skills...
  24. pmc Combining a symptoms index with CA 125 to improve detection of ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 113:484-9. 2008
    ....
  25. doi request reprint Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle WA 98195, USA
    Gynecol Oncol 110:146-51. 2008
    ..To determine the nature and degree of toxicity, response rate, quality of life (QOL), and progression-free interval in women with platinum-resistant refractory ovarian or peritoneal cancer receiving weekly topotecan and gemcitabine...
  26. pmc Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Altern Complement Med 19:714-20. 2013
    ..This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together...
  27. pmc Factors affecting risk of mortality in women with vaginal cancer
    Chirag A Shah
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle, Washington 98195 6460, USA
    Obstet Gynecol 113:1038-45. 2009
    ..To estimate the current effect of demographics, pathology, and treatment on mortality among women with vaginal cancer...
  28. doi request reprint FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 120:296-9. 2011
    ..To characterize clinical features of vulvar Paget's disease, and examine the quantity of immunosuppressive regulatory T-cells in vulvar Paget's tissue...
  29. doi request reprint Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
    Chirag A Shah
    University of Washington Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Seattle, Washington 98195, USA
    Gynecol Oncol 109:215-9. 2008
    ..Forty percent of women with ovarian cancer have circulating free tumor DNA. We sought to determine if the tumor immune infiltrate varied based on tumor p53 mutation status or presence of circulating tumor DNA...
  30. pmc Patterns of spread and recurrence of sex cord-stromal tumors of the ovary
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 122:242-5. 2011
    ..To confirm these findings, we evaluated pathologic findings in women undergoing surgical management of sex cord-stromal tumors in the Seattle metropolitan area...
  31. ncbi request reprint A six-year study of surgical teaching and skills evaluation for obstetric/gynecologic residents in porcine and inanimate surgical models
    Gretchen M Lentz
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
    Am J Obstet Gynecol 193:2056-61. 2005
    ....
  32. pmc Accuracy of ovarian and colon cancer risk assessments by U.S. physicians
    Laura Mae Baldwin
    Department of Family Medicine, University of Washington, Box 354982, Seattle, WA, 98195 4982, USA
    J Gen Intern Med 29:741-9. 2014
    ..Inaccurate cancer risk assessment is one potential cause of this mismatch...
  33. pmc Identification of ovarian cancer symptoms in health insurance claims data
    Sean M Devlin
    Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington 98195 9455, USA
    J Womens Health (Larchmt) 19:381-9. 2010
    ....
  34. ncbi request reprint Alternate molecular genetic pathways in ovarian carcinomas of common histological types
    Julia Willner
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
    Hum Pathol 38:607-13. 2007
    ..Mutations in p53, PIK3CA, PTEN, and CTNNB1 account for most EC tumors; most CC remain unexplained. EC/CC histology is a favorable prognostic factor...
  35. doi request reprint An evaluation of cervical cancer in women age sixty and over
    Katrina V Fox
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Gynecol Oncol 109:53-8. 2008
    ..To assess prior cervical cancer screening, stage at time of diagnosis and outcome in women sixty years of age and over with cervical cancer...
  36. ncbi request reprint Ovarian cancer: patterns of surgical care across the United States
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 103:383-90. 2006
    ..To describe the primary surgical procedures and procedures for intraoperative and postoperative complications, and factors associated with these procedures, in women with ovarian cancer...
  37. doi request reprint Changing the paradigm in surgical education
    Barbara A Goff
    University of Washington School of Medicine, Seattle, Washington, USA
    Obstet Gynecol 112:328-32. 2008
    ..Identifying more effective methods to teach and assess surgical skills will benefit not only our trainees but also the patients for whom we care...
  38. ncbi request reprint Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
    Gynecol Oncol 118:43-6. 2010
    ..Recent studies have suggested inferior outcomes for elderly women with ovarian cancer. Our goal was to evaluate neoadjuvant chemotherapy versus primary cytoreduction in elderly women...
  39. pmc Trends in treatment of advanced epithelial ovarian cancer in the Medicare population
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 122:100-6. 2011
    ..This study evaluated patterns of care, frequency of completion of recommended therapy and factors associated with sequencing of therapy...
  40. ncbi request reprint Adverse events associated with complementary and alternative medicine use in ovarian cancer patients
    Erin S Sweet
    Bastyr University, Kenmore, WA, USA
    Integr Cancer Ther 12:508-16. 2013
    ....
  41. pmc Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers
    Karen M Chisholm
    Department of Genome Sciences, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA
    Cancer Genet Cytogenet 183:41-8. 2008
    ..In those tumors with retention of part of chromosome 17, LOH margins suggest that a high Alu content may have a role in the deletions...
  42. ncbi request reprint Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers
    Minh D Dao
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195 6460, USA
    Gynecol Oncol 130:295-9. 2013
    ..To evaluate patterns of recurrence for ovarian, fallopian tube, and primary peritoneal cancer patients undergoing extended treatment with bevacizumab (BEV)...
  43. doi request reprint Involvement in decision-making about treatment and ovarian cancer survivor quality of life
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 124:465-70. 2012
    ....
  44. ncbi request reprint Self-assessment of resident surgical skills: is it feasible?
    Lynn S Mandel
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195 6460, USA
    Am J Obstet Gynecol 193:1817-22. 2005
    ....
  45. doi request reprint Pelvic exenteration in the age of modern chemoradiation
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 121:131-4. 2011
    ..To examine outcomes after pelvic exenteration in women treated with modern chemoradiation and surgical techniques...
  46. ncbi request reprint Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium
    Elizabeth M Swisher
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 N E Pacific St, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 101:429-35. 2006
    ..Define the maximum tolerated dose of weekly gemcitabine given concomitantly with standard weekly cisplatin and pelvic radiotherapy for primary treatment of cervical cancer...
  47. pmc Value of symptom-triggered diagnostic evaluation for ovarian cancer
    M Robyn Andersen
    Fred Hutchinson Cancer Research Center and School of Public Health and Community Medicine, University of Washington, Exponent Health Sciences, and the Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington
    Obstet Gynecol 123:73-9. 2014
    ..To evaluate the potential harms and ovarian cancer outcomes associated with symptom-triggered diagnostic evaluation of all women with symptoms of ovarian cancer...
  48. pmc Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma
    Tilley Jenkins Vogel
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
    Transl Oncol 5:247-51. 2012
    ..Angiogenesis is critical in neoplastic growth and metastasis. We sought to determine whether circulating neoplastic DNA results from alterations in the balance of angiogenesis activators and inhibitors...
  49. ncbi request reprint Training the next generation of minimally invasive surgeons
    Michael F Fialkow
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, USA
    J Minim Invasive Gynecol 16:136-41. 2009
    ..Although many questions remain about how to optimally apply and evaluate the educational tools being developed, it appears certain that surgical simulation, in some form, is the educational paradigm of the present and future...
  50. pmc MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival
    Kaitlyn Wurz
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195 6460, USA
    Genes Chromosomes Cancer 49:577-84. 2010
    ..01). In contrast, CDKN1B expression was not associated with miR-221 or miR-222 expression. Neither somatic mutations nor methylation of the studied region explained the alterations in miR-221 and miR-222 expression in most carcinomas...
  51. ncbi request reprint A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS)
    Amy L VanBlaricom
    Department of Obstetrics, University of Washington, Madigan Army Medical Center, Seattle, WA, USA
    Am J Obstet Gynecol 193:1856-65. 2005
    ..The purpose of this study was to develop an effective curriculum to teach hysteroscopy, as well as to develop an objective assessment instrument (OSATS)...
  52. doi request reprint Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey
    Hajar Kadivar
    Department of Family Medicine, University of Washington, Seattle, Washington, USA
    Am J Prev Med 43:231-9. 2012
    ..Little is known about the prevalence of physicians offering nonrecommended breast or colorectal cancer screening for young women...
  53. ncbi request reprint Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle 98195, USA
    JAMA 291:2705-12. 2004
    ..Women with ovarian cancer frequently report symptoms prior to diagnosis, but distinguishing these symptoms from those that normally occur in women remains problematic...
  54. ncbi request reprint Evaluation of postoperative fever: usefulness and cost-effectiveness of routine workup
    Sarah H de la Torre
    Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, 98195, USA
    Am J Obstet Gynecol 188:1642-7. 2003
    ..This study was undertaken to determine which investigative tools are of most clinical benefit in a routine postoperative fever workup and to describe which postoperative patients require closer investigation at the time of fever...
  55. ncbi request reprint Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer
    Elizabeth M Swisher
    Division of Medical Genetics, University of Washington, Seattle, WA, USA
    Am J Obstet Gynecol 193:662-7. 2005
    ..Free tumor DNA in body fluids may be an important biomarker. We tested whether tumor-specific mutated p53 DNA can be detected in blood and peritoneal fluid from women with epithelial ovarian cancer...
  56. ncbi request reprint Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy
    Julie D Lamb
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195 6460, USA
    Am J Obstet Gynecol 194:1702-9. 2006
    ..We hypothesized that older age and having a BRCA1 mutation would be predictors for tubal or ovarian neoplasia and that a careful surgical and pathologic protocol would lead to a low rate of subsequent primary peritoneal cancer...
  57. ncbi request reprint Surgical skills assessment: a blinded examination of obstetrics and gynecology residents
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, 98195 6460, USA
    Am J Obstet Gynecol 186:613-7. 2002
    ..Our goal was to establish the feasibility, reliability, and validity of our surgical skills assessment instrument when administered in a blinded fashion...
  58. pmc The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes
    Heidi J Gray
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Obstet Gynecol Int 2010:743794. 2010
    ..168). Overall survival in the abandoned group was 73% versus 80% in the completed group (P = .772). Conclusion. The practice of abandoning a planned radical hysterectomy for unexpected metastatic disease may not worsen the outcome...
  59. ncbi request reprint The significance of psammoma bodies in screening cervical cytologic smears
    Howard G Muntz
    Gynecology and Gynecologic Oncology Section, Department of Surgery, Virginia Mason Medical Center, Seattle, WA 98111 0900, USA
    Am J Obstet Gynecol 188:1609-12; discussion 1612-4. 2003
    ....
  60. ncbi request reprint Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, 98195 6460, USA
    Am J Obstet Gynecol 188:1556-62; discussion 1562-4. 2003
    ....